Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice
Journal of Prescribing Practice · 02.05.2026 · 8 (5) · 190-192
DOI: 10.12968/jprp.2026.0051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Prescribing Practice, erschienen am 02.05.2026. Verfasst von Aysha Mendes. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Aysha Mendes discusses the introduction of rozanolixizumab, which will provide more choice and targeted treatment options for generalised myasthenia gravis, with important considerations for prescribers concerning escalation, delivery and patient outcomes
Zitieren
APA
Mendes, A. (2026). Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice. Journal of Prescribing Practice, 8(5), 190-192. https://doi.org/10.12968/jprp.2026.0051
Vancouver
Mendes A. Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice. Journal of Prescribing Practice. 2026;8(5):190-192. doi:10.12968/jprp.2026.0051
BibTeX
@article{Mendes2026,
author = {Mendes, Aysha},
title = {Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice},
journal = {Journal of Prescribing Practice},
year = {2026},
volume = {8},
number = {5},
pages = {190--192},
doi = {10.12968/jprp.2026.0051}
}
EUVIMED